secwatch.observer — SEC 8-K summary
======================================

Issuer:     RANGE IMPACT, INC. (RNGE)
CIK:        0001438943
Form:       8-K
Filed at:   2021-08-10T23:59:59+00:00
Accession:  0001493152-21-019108
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vitality Biopharma receives FDA Orphan Drug Designation for VBX-100 for pediatric ulcerative colitis
--------------------------------------------------------------------------------

- FDA granted Orphan Drug Designation to VBX-100, a glycosylated cannabinoid prodrug, for pediatric ulcerative colitis.
- Orphan Drug Designation provides seven-year market exclusivity upon FDA approval, tax credits, and fee exemptions.
- Vitality has developed over 100 novel glycosylated cannabinoid compounds using proprietary enzymatic bioprocessing.
- VBX-100 targets inflammatory conditions of the gastrointestinal tract; company plans to accelerate research.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438943/000149315221019108/0001493152-21-019108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438943/000149315221019108/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-019108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer